There are two differences today than what we had last wèek.
The first is the SOI
The second is we are now able to dose the 10 people on the waitlist for the Cd17 trial, and have enough money to keep the ASX obligations.
The share price touching .008c was a blip, which one holder slept through. The share price was .005c with the occasional bounce to .004c and .006c. And money in the bank last month meant we could only dose 1 or 2 more arms in the Cd17 trial.
Yes the SOI is now huge. But market cap is still small. But now if we get good news, it will be able to run. This is the best position CHM has been in since the GBM trial was shelved.
The options, if in the money will keep the bank account in the green. This risk is now removed until mid next year. Reread the article where partnering was discussed and see what they said they needed to achieve that.
This is a very high risk end of the market. CHM is trialling CarT drugs. The cost of this is huge. Cash burn is huge because of this. And this is the major risk to this investment. Today helped reduce that risk.
There are 4 centres now for the Cd17 trial. we now have the money to get all of them working. Hopefully this happens and news flow is quicker because of this. We were not in that position last week.
To make money out of CHM we need the pipeline to progress and be successful. We can now progress it, we just need the drug to work now.
CHM Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)